Navigation Links
Frantz Medical Group Announces the Promotion of Stephanie Harrington to Chief Operating Officer
Date:5/9/2011

CLEVELAND, May 9, 2011 /PRNewswire/ -- Mentor, Ohio-based Frantz Medical Group announced the immediate promotion of Stephanie A. S. Harrington, M.S. to Chief Operating Officer.  Ms. Harrington joined Frantz Medical Group in 2005 as Vice President, Research & Business Development. Since that time, she has assumed increased responsibilities such as direct management of regulatory affairs and quality assurance, manufacturing and molding/tool room operations. Ms. Harrington has also served as the Chief Operating Officer for VasoStar (cardiovascular minimally invasive device to open arterial blockages), CardioStar (non-invasive blood pressure monitor) and NanoMed (cardiovascular stent surface technology), and the Vice President of Merlot Orthopedics (orthopedic fixation devices).  Each of these companies is a Frantz Medical joint venture/equity company, and she will continue to directly manage these various operations.

Ms. Harrington is a Chemical Engineer with an undergraduate degree from the University of Maryland, and graduate degree from Stanford University.  She has been focused in the medical device field for the past 16 years with extensive experience in new product development, regulatory affairs and quality assurance. She has previously held senior management positions at Imalux and STERIS.

Ms. Harrington has spearheaded the cardiovascular and orthopedic R&D initiatives at Frantz Medical Group, including industrial-sponsored and state and national funded research grants with leading institutional partners such as Cleveland Clinic, Global Cardiovascular Innovation Center, Stanford University, and University of Virginia. Ms. Harrington will be involved in all operational aspects for the Frantz Medical Group of companies, including Frantz Tool & Design, and will serve as an advisor for tactical and strategic input on Frantz Medical Group's bioscience seed initiatives.

"I highly value Stephanie's input and leadership in all aspects of our operations, and look forward to her even further expanded role as my colleague in Frantz Medical Group," said Mark G. Frantz, Chairman and CEO.

About Frantz Medical Group

Frantz Medical Group (FMG) has been transforming innovative concepts into commercially successful medical devices, both electromechanical and disposable products, since 1979.   As an ISO 13485-certified, FDA-registered medical device company, FMG offers inventors and early-stage companies the infrastructure to design, verify, and transfer to production new medical devices efficiently and cost-effectively.   FMG's manufacturing capabilities include high-volume injection molding, assembly, inspection, and packaging – with both clean room and open manufacturing areas.   For high volume products, FMG designs products for later-stage automation, and has implemented in-house automation, lowering labor requirements and per-piece costs.

For further information regarding Frantz Medical Group, please refer to the website: www.frantzgroup.com.


'/>"/>
SOURCE Frantz Medical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Globus Medical Raises $110 Million in Series E Financing Round
6. Quark Pharmaceuticals Appoints New Chief Medical Officer
7. Boston University Biomedical Engineers Find Chink in Bacterias Armor
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
11. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the Phase ... an anti-P-selectin antibody, reduced the median annual rate of ... placebo (1.63 vs 2.98, p=0.010) in patients with or ... the data are being featured in the official press ... Hematology (ASH) Annual Meeting and presented during the Plenary ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice ... on I learned that medicine is about more than making diagnoses and prescribing medicine,” ...
(Date:12/2/2016)... ... ... Mediaplanet is proud to announce the launch of its ... therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage their ... the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This is ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
Breaking Medicine News(10 mins):